Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 7/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20037592 | 0.82 | ALDH1A1 (0.50) | PRMT5WDR77MEN1KMT2AHRH3 | |
| SCHEMBL22876994 | 0.82 | PRMT5 (0.46) | PRMT5WDR77MEN1KMT2AMCHR1 | |
| SCHEMBL21414330 | 0.79 | ALDH1A1 (0.47) | PRMT5WDR77MEN1KMT2AHRH3 | |
| SCHEMBL20037425 | 0.76 | PRMT5 (0.44) | PRMT5WDR77KMT2AMCHR1ATM | |
| SCHEMBL17660303 | 0.76 | LMNA (0.50) | PRMT5WDR77MEN1KMT2AHRH3 | |
| SCHEMBL20037661 | 0.74 | PRMT5 (0.38) | PRMT5WDR77MEN1KMT2AHRH3 | |
| SCHEMBL20203451 | 0.73 | ALDH1A1 (0.51) | PRMT5WDR77MEN1KMT2AATM | |
| SCHEMBL12028959 | 0.72 | HRH3 (0.47) | PRMT5WDR77MEN1KMT2AHRH3 | |
| SCHEMBL4547913 | 0.72 | HRH3 (0.50) | PRMT5WDR77HRH3ALDH1A1 | |
| SCHEMBL20203391 | 0.72 | PRMT5 (0.47) | PRMT5WDR77MEN1KMT2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | disclosed |
| EP-3546458-A1 | PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018097297-A1 | PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 帝人ファーマ株式会社 | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | PRMT5 1943/4885WDR77 1134/4885MEN1 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.